What to know about COVID variant NB.1.8.1 causing 'razor blade throat'
The variant, known as NB.1.8.1, has been nicknamed by some as "razor blade throat" due to the painful symptom.
MORE: Why are more than 300 people in the US still dying from COVID every week?
Data from the open global genome sequencing database GISAID shows the new variant has been detected in several states, including New York, Illinois, Texas and California.
Public health experts told ABC News there is no cause for serious concern yet because the virus does not appear to be more severe than previous variants and there are steps that can be taken to protect yourself.
NB.1.8.1 derives from the recombinant variant XVD.1.5.1, which is a descendant of the omicron variant.
The first sample of NB.1.8.1 was collected on Jan. 22, according to the World Health Organization (WHO). It was first detected in China and other parts of Asia before spreading to Europe.
It was designated as a "variant under monitoring" by the WHO, meaning it may require prioritized attention and monitoring but is not as serious as a "variant of interest" or a "variant of concern."
As of the week ending June 7, NB.1.8.1 is the second most dominant variant in the U.S., accounting for an estimated 37% of cases, according to the Centers for Disease Control and Prevention (CDC).
The virus appears to be more transmissible because there appear to be changes to the spike protein, which is what the virus uses to attach to and infect cells, said Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco.
It also seems to attach more easily to ACE2 receptors, which are proteins found on the surface of cells and how the virus that causes COVID enters cells, he told ABC News.
NB.1.8.1 doesn't yet appear to be causing increases in cases or in hospitalizations with rates remaining "stable" so far, according to Chin-Hong.
The variant has also been called "Nimbus," which appears to have been coined on X by T. Ryan Gregory, a Canadian professor of evolutionary biology.
"Nimbus is a catchy, quick name, and it also includes an 'N' and a 'B' from the lineage, which is NB.1.8.1. So it's easier for people to be able to say these monikers for COVID, rather than remember the actual lineage," said Dr. Alok Potel, a pediatrician at Stanford Children's Health and an ABC News contributor.
"But I think it's important also because it keeps people paying attention to new COVID variants that can be different in terms of infectivity and in terms of spread," he added.
MORE: What we still don't know about COVID 5 years after the WHO declared a pandemic
Experts said they are not sure if the painful sore throat is just a symptom that people are talking about or a distinctive symptom of this variant.
It's also unclear if the "razor blade throat" is more common in those who are more up to date on vaccination compared to those who are not up to date.
"I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum," Chin-Hong said.
There is currently no evidence that NB.1.8.1. causes more severe disease or is more likely to cause hospitalization, according to Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center in Nashville,
MORE: 5 years ago, the WHO declared COVID a pandemic. Here's a look at the disease by the numbers
"But of course, there are people in high-risk groups that are still at risk of being hospitalized should they become infected," he told ABC News.
There are no other symptoms outlined that are specific to NB.1.8.1 by the CDC.
Symptoms listed by the health agency still include sore throat, cough, fever, chills, shortness of breath, difficulty breathing, congestion, runny nose, loss of taste or smell, fatigue, muscle aches, body aches, headache, nausea, vomiting or diarrhea.
The experts recommend that high-risk Americans receive a vaccine twice a year as recommended by the CDC.
The CDC also currently recommends most adults aged 18 and older receive an updated 2024-2025 vaccine and that parents of children between ages 6 months to 17 years discuss the benefits of vaccination with a health care provider.
COVID-19 also tends to spike in the late summer and early fall, so people should consider opening windows to increase ventilation, wearing a mask in certain situations and avoiding crowded areas, Schaffner said.
"Time to stream a movie, as I like to say, rather than going to the movies," he added.
Patel said it's important to practice good hygiene such as proper hand-washing and covering your mouth when coughing or sneezing.
He also recommended that people test if they are symptomatic and said over-the-counter rapid at-home tests work.
"Getting infected with COVID and other infectious diseases is not necessarily life or death, but it can still be very debilitating." Patel said. "It can cause people to miss work, to spread the virus, to get people who are higher risk sick and there's still an untold amount of people who have long COVID."
He added, "So, we don't want to look at COVID as just another common cold, because there's still so much we're learning about it, and there's still so many possibilities with this virus continuing to mutate, if we let it."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Advanced Ophthalmology Technology Market to Hit Valuation of US$ 16.01 Billion by 2033
The market is rapidly advancing, driven by an aging population's needs. A clear segmentation is emerging hospitals focus on complex, high-margin procedures, while specialized centers increasingly absorb routine surgeries. Chicago, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global advanced ophthalmology technology market was valued at US$ 8.78 billion in 2024 and is expected to reach US$ 16.01 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025–2033. The future of the advanced ophthalmology technology market is being written today in research labs and clinical trials around the world. A robust pipeline of innovative treatments, particularly in areas like gene therapy for inherited and chronic eye diseases, holds the promise of not just managing but potentially reversing vision loss. The intense research activity is also reflected in the continuous stream of new patents being filed, protecting the intellectual property that will form the basis of next-generation devices and therapies. This forward-looking activity, combined with a growing and specialized workforce, ensures a long-term trajectory of growth and transformative breakthroughs for the industry. Download Sample Pages: The scale of innovation is evident in patent and clinical trial data. In 2024 alone, 1,393 international patents related to vision science were published. Ophthalmic Sciences, an innovator in the field, holds 6 total patents, with 3 of those being active globally. The clinical trial landscape is equally vibrant. The RGX-314 gene therapy trial for wet AMD has enrolled 465 patients, while the SOL-R registrational trial for AXPAXLI in the same condition has a target randomization of at least 555 patients. A search on reveals 22 active clinical studies focused on gene therapy for wet AMD. Supporting this innovation is a skilled workforce; the mean number of ophthalmologists per 100,000 inhabitants across Europe is 9.36, with nations like Italy having 12.28 practicing ophthalmology physicians per 100,000 persons in 2024. Niche markets are also showing strong growth, with the U.S. dry eye treatment devices market reaching approximately $99.7 million in 2024 to serve the around 16 million people diagnosed with Dry Eye Disease. Key Findings in Advanced Ophthalmology Technology Market Market Forecast (2033) US$ 16.01 billion CAGR 6.9% Largest Region (2024) North America (39%) By Type Diagnostic (58%) By End Use Hospitals (41%) Top Drivers Rising prevalence of age-related eye diseases boosts technology demand. Continuous technological advancements are improving diagnostic and surgical outcomes. Growing patient awareness regarding the importance of early eye diagnosis. Top Trends Artificial intelligence integration is revolutionizing diagnostics and treatment planning. Increasing surgeon and patient preference for minimally invasive procedures. Shift of routine surgeries from hospitals to specialized outpatient centers. Top Challenges The high acquisition and maintenance costs of advanced ophthalmic technologies. A growing shortage of skilled ophthalmologists to operate new equipment. Complex reimbursement policies and stringent regulatory approval processes. Financial Titans Dominating the Global Advanced Ophthalmology Technology Market Landscape The financial health of key industry players provides a powerful indicator of the market's robust vitality and sustained growth potential. These leading companies are demonstrating exceptional performance through impressive sales figures and strong operational cash flows, reflecting the high demand for their innovative products. Their financial strength not only solidifies their market position but also enables continued investment in the research and development that drives the entire sector forward. A close examination of their financial reports reveals a clear and compelling narrative of a thriving and profitable industry, setting a confident tone for future expansion and shareholder value in a competitive environment. Alcon, a global leader in the advanced ophthalmology technology market, showcases remarkable financial strength, reporting total net sales of $9.8 billion for the full year 2024. The performance was robust across its divisions, with Surgical net sales reaching $5.5 billion and Vision Care net sales hitting $4.3 billion. The company achieved a record cash from operations of $2.1 billion and a record free cash flow of $1.6 billion. A breakdown of 2024 quarterly performance further illustrates this momentum: Q1 sales were $2.4 billion, with $341 million in cash from operations and $229 million in free cash flow. Q2 sales increased to $2.5 billion, with Surgical net sales at $1.4 billion and Vision Care sales reaching $2.2 billion in the first half. Q3 saw net sales of $2.4 billion, with the Surgical segment contributing $1.34 billion, and Q4 sales were $2.5 billion. Bausch + Lomb also posted strong full-year 2024 revenues of $4.791 billion, with its Surgical segment accounting for $843 million and generating $232 million in cash flow from operations for the year. The company's third quarter revenue was $1.196 billion, with the surgical segment at $206 million and cash flow from operations at $154 million, while Q4 surgical revenue was $231 million. Topcon's Eye Care business reported first-half fiscal year 2024 sales of ¥37.1 billion (€224 million), with a full-year revenue forecast of ¥82.0 billion (€495 million). The combined North American and European half-year sales for Topcon were approximately ¥60 billion, underscoring the strong international demand within the advanced ophthalmology technology market. Unprecedented Surgical Volumes Propel Growth in the Advanced Ophthalmology Technology Market The sheer volume of surgical procedures performed worldwide is a primary engine powering the expansion of the market. An aging global population and the increased prevalence of conditions like cataracts are driving millions of patients to seek surgical solutions. Simultaneously, the introduction of safer, faster, and more effective minimally invasive techniques has broadened patient acceptance and accessibility. The statistics on cataract, LASIK, and SMILE procedures paint a vivid picture of a sector experiencing immense procedural demand. Such high volumes necessitate a continuous supply of advanced surgical equipment, implants, and consumables, creating a powerful and self-reinforcing cycle of growth and innovation. By 2025, an estimated 28 million cataract surgeries are performed annually across the globe, which translates to roughly 75,000 procedures every single day. The minimally invasive refractive procedure, Small Incision Lenticule Extraction (SMILE), has already surpassed 10 million procedures performed worldwide as of the end of 2024 in the advanced ophthalmology technology market. Since its FDA approval in 2016, an average of more than 1 million people have chosen SMILE each year, a procedure now offered by over 2,000 surgeons in 70 countries. The demand for intraocular lenses (IOLs) is staggering, with a projected 200 million patients requiring IOL implantation by 2025. In the United States alone, approximately 800,000 LASIK procedures are performed annually. Growth is also pronounced in developing markets; the estimated cataract surgery rate in China is expected to reach 350 per 100,000 people by 2025. Illustrating global outreach efforts, one specific aid project in Cambodia has already provided free surgery to 3,138 cataract patients, highlighting the vast unmet need that technology can address. Next-Generation Diagnostic and Monitoring Tools Redefine Patient Care and Market Demand Early and accurate diagnosis is the cornerstone of effective ophthalmology, and advanced diagnostic equipment is at the forefront of advanced ophthalmology technology market. Technologies like Optical Coherence Tomography (OCT) have become indispensable, providing high-resolution, cross-sectional images of the retina that enable the detection and management of numerous sight-threatening diseases. The growing prevalence of conditions such as diabetic retinopathy and age-related macular degeneration (AMD) is directly fueling the demand for these sophisticated diagnostic platforms. The market is responding with increasingly powerful and user-friendly devices, including handheld and automated units, that are expanding access to high-quality care from specialized clinics to primary care settings. The adoption rate of these technologies is reflected in strong sales figures, with 18,700 handheld OCT units sold globally in 2023. The clinical utility is immense, with over 50 million diabetes-related OCT scans performed annually. The technology's application in the advanced ophthalmology technology market is even extending beyond human medicine, with over 500 veterinary OCT devices now in use for animal diagnostics. Industry leader Topcon has sold over 20,000 units of its Maestro OCT system globally as of late 2023, a testament to the device's popularity and reliability. The urgency for such advanced diagnostic capability is underscored by daunting projections; approximately 200 million individuals are expected to be affected by AMD by the year 2040, creating a massive patient population in need of vigilant monitoring. Premium Intraocular Lenses Signal a Paradigm Shift in Cataract Surgery Outcomes The intraocular lens (IOL) segment has evolved far beyond simple vision correction, entering an era of premium technology that offers patients a range of lifestyle-enhancing benefits. Today's advanced IOLs can correct presbyopia, astigmatism, and other refractive errors, often reducing or eliminating a patient's dependence on glasses after cataract surgery. This shift towards premium, high-performance lenses represents a significant value-add in the cataract surgery space, driving revenue growth and patient satisfaction. As patient expectations rise, so does the demand for technologies that deliver superior visual outcomes, making the premium IOL sector a key growth area within the advanced ophthalmology technology market. The market's scale is substantial, with annual IOL lens unit shipments reaching 42 million in 2023, corresponding with the roughly 25 million cataract surgeries performed that year. The procedural efficiency in modern clinics further fuels this demand. High-volume cataract clinics now see surgeons implanting an average of 1,200 lenses per year. At an institutional level, surgical centers are now performing an average of 4,500 cataract cases annually. These high procedural volumes, combined with the increasing adoption of premium IOL technologies, create a powerful economic engine that supports ongoing innovation in lens design, materials, and functionality. Robust Investment and Venture Capital Fueling Future Ophthalmic Technology Market Breakthroughs A vibrant ecosystem of investment is crucial for nurturing the next wave of innovation, and the ophthalmology sector is attracting significant capital from diverse sources. Major corporations in the advanced ophthalmology technology market are channeling billions into research and development, while a dynamic venture capital landscape is providing essential funding for startups and emerging technologies. This influx of capital is accelerating the development of groundbreaking therapies, more advanced surgical devices, and sophisticated software platforms. The high level of merger and acquisition activity further signals a mature and attractive market where proven innovations are being rapidly integrated into larger commercial platforms, promising a future rich with transformative solutions. The financial commitment to innovation is clear. Alcon's R&D investment for the twelve months ending March 31, 2025, stood at an impressive $899 million, with annual R&D expenses for 2024 totaling $876 million. Across the industry, total investment in ophthalmology in 2024 exceeded $6.3 billion. The market also saw 18 merger and acquisition transactions in 2024, indicating strong consolidation and strategic growth activity. The venture capital pipeline is equally robust, with financing in ophthalmology for the first quarter of 2025 reaching $515.7 million across 21 transactions. As of May 2025, U.S. ophthalmology companies had already raised $597 million in equity funding through 15 rounds. Looking at a longer trend, the total venture capital investment in the ophthalmic devices sector over the last 10 years has amounted to a formidable $2.51 billion. Artificial Intelligence Integration Revolutionizes Diagnostics in the Advanced Ophthalmology Technology Market Artificial intelligence (AI) is rapidly transitioning from a theoretical concept to a practical and powerful clinical tool within the market. AI algorithms are now capable of analyzing retinal images with remarkable speed and accuracy, detecting early signs of diseases like diabetic retinopathy long before they might be caught by traditional methods. This technology is democratizing access to specialist-level diagnostics, enabling screening to be performed in primary care settings and reducing the burden on ophthalmologists. The efficiency and precision of AI are not just improving patient outcomes but also creating new operational efficiencies for healthcare systems. The real-world adoption of AI is accelerating in the advanced ophthalmology technology market. As of mid-2024, 198 AI-equipped cameras have been deployed across five U.S. health systems, covering a population of approximately 151,000 patients with diabetes. In the United States, three FDA-approved AI algorithms for diabetic retinopathy screening were available as of 2025. The clinical uptake is evident in reimbursement data, with more than 15,000 Medicare claims filed for AI diabetic retinopathy screening algorithms since 2022. The efficacy of these systems was proven in a clinical trial involving 900 patients, which led to FDA approval for one AI eye exam system. The speed of these platforms is a key advantage; scans using the AEYE-DS diabetic retinopathy algorithm are designed to produce actionable results in under 60 seconds. Surgical Laser Precision and Speed Setting New Benchmarks for Ophthalmic Procedures Modern excimer and femtosecond lasers are the technological cornerstones of refractive and cataract surgery, and continuous innovation is pushing the boundaries of what is possible in the advanced ophthalmology technology market. Today's surgical laser platforms offer unparalleled precision, speed, and safety, enabling surgeons to perform highly customized and predictable procedures. Advancements in eye-tracking technology, laser pulse frequency, and treatment algorithms are leading to better visual outcomes, faster recovery times, and an enhanced patient experience. These technological leaps are critical for meeting the high expectations of patients seeking freedom from corrective eyewear and are a major factor in the continued growth of the refractive surgery market. The Bausch + Lomb TENEO Excimer Laser Platform exemplifies this cutting-edge technology with its impressive performance metrics. The platform boasts an exceptionally fast ablation time of approximately 1.2 seconds per diopter, minimizing procedure time and improving patient comfort. Supporting this speed is an advanced eye-tracker that operates at an incredible 1,740 Hz, ensuring the laser remains perfectly centered on the eye even with involuntary movements. The TENEO laser itself operates at a high speed of 500 Hz, allowing for swift and highly precise corneal tissue ablation. These specific, quantifiable advancements are what define the leading edge of the advanced ophthalmology technology market, delivering tangible benefits to both surgeons and patients. Customize the Data Scope to Match Your Objectives: Strategic Private Equity Investment and Remote Care Reshape Ophthalmic Service Delivery The business landscape of ophthalmology is being actively reshaped by two powerful forces: strategic investment from private equity and the rise of remote care models. Private equity firms are increasingly drawn to the sector's stable growth and opportunities for consolidation, leading to a wave of practice acquisitions. This trend is creating larger, more efficient practice groups with greater resources for technology adoption. In parallel, tele-ophthalmology platforms are gaining traction, leveraging technology to conduct remote eye exams and consultations. This remote care model is expanding access to services, particularly in underserved areas, and creating new, flexible models for delivering eye care. The impact of private equity is significant in the advanced ophthalmology technology market, with over 330 private equity-backed physician practice management (PPM) transactions recorded in ophthalmology over the last five years. This consolidation trend is fundamentally changing the structure of service delivery in the market. Simultaneously, the telehealth revolution is making its mark. The remote examination platform from DigitalOptometrics, for instance, has already conducted over 2 million remote exams. This number highlights a clear and growing acceptance of remote technologies by both patients and providers, signaling a permanent shift in how ophthalmic services can be delivered and scaled. Global Advanced Ophthalmology Technology Market Major Players: Alcon Allergan Bausch + Lomb Carl Zeiss Meditec EssilorLuxottica Heidelberg Engineering HOYA Johnson Johnson Vision NIDEK CO., LTD Novartis Ophthotech Corporation Regeneron Pharmaceuticals, Inc. Roche Samsung Topcon Other Prominent Players Key Market Segmentation: By Type Diagnostic Therapeutic By End Use Hospitals Ambulatory Surgical Centers (ASCs) Ophthalmic Clinics Others By Region North America Europe Asia Pacific Middle East & Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Map shows more than 1,300 measles cases across U.S.
In 2025, the United States has recorded the most measles cases in more than 30 years, Centers for Disease Control and Prevention data shows. A large share of the infections were connected to an outbreak in West Texas that led to the deaths of two children. The number of cases in Texas alone grew to over 760 before the state declared it officially over in August, while total cases nationwide have topped 1,300, with infections confirmed in at least 39 states. Measles is one of the most contagious infectious diseases, and in some cases, can cause severe infections in the lungs and brain that can lead to cognitive issues, deafness or death. But doctors and health officials say the vaccine, which is normally given as part of the combination measles-mumps-rubella (MMR) vaccine, is highly safe and effective. While most people's symptoms improve, about 1 in 5 unvaccinated people who get measles will be hospitalized. About 1 out of every 1,000 children with measles will develop brain swelling that can lead to brain damage, and up to 3 of every 1,000 children who become infected will die, the CDC says. The largest outbreak so far this year has been in West Texas, but cases have been reported in other states around the country, as well. The CBS News data team is tracking confirmed measles cases nationwide as new data is released by state health departments and the CDC. (The map below is updated on Wednesdays when the CDC releases its latest weekly numbers.) The Texas outbreak primarily affected children and teenagers, nearly all of whom were unvaccinated or had an unknown vaccination status. State and local health officials confirmed the first patient who died was an unvaccinated school-aged child, and the second was an unvaccinated 8-year-old girl. Neither of the children had underlying health conditions, the Texas health department said. New Mexico also reported the death of an adult with measles. The last measles death in the U.S. before this year was in 2019, when a 37-year-old man died from measles complicated by meningitis in California, according to CDC data. Until now, the highest number of confirmed cases in the U.S. in recent years was 1,274 in 2019, driven by outbreaks in New York, California and Washington state, but most years the total has been much lower. Health experts point to lower vaccination rates as a reason for increases in preventable diseases like the measles. CDC data shows about 93% of kindergarteners in the U.S. were vaccinated against measles during the 2021-2022 school year and only 92.7% in the 2023-2024 school year. This is down from 95.2% during the 2019-2020 school year — a critical threshold to keep people safe. "When more than 95% of people in a community are vaccinated, most people are protected through community immunity (herd immunity)," the CDC states. Health and Human Services Secretary Robert F. Kennedy Jr., who has a history of making false and misleading claims about vaccines, voiced support for vaccination as the deadly outbreak spread in the Southwest. "We encourage people to get the measles vaccine," Kennedy told CBS News chief medical correspondent Dr. Jon LaPook in an interview April 8, marking the first time Kennedy has publicly urged people to get the measles vaccine since becoming HHS secretary. Asked by LaPook what the federal government's official position on the vaccine is, Kennedy reiterated, "The federal government's position, my position, is that people should get the measles vaccine," but added, "The government should not be mandating those." Alaska Sen. Dan Sullivan on the Trump-Putin summit, sanctions and more A robotics activist's remarkable crusade A look at Taylor Swift's marketing strategy as upcoming album makes new headlines Solve the daily Crossword

Yahoo
10 minutes ago
- Yahoo
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) i Sign in to access your portfolio